These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35676019)

  • 21. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
    Saint-Laurent Thibault C; Moorjaney D; Ganz ML; Sill B; Hede S; Yuan Y; Gorsh B
    J Med Econ; 2017 Jul; 20(7):692-702. PubMed ID: 28294645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
    Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
    Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
    Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
    Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
    J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    Alonso S; Riveiro-Barciela M; Fernandez I; Rincón D; Real Y; Llerena S; Gea F; Olveira A; Fernandez-Carrillo C; Polo B; Carrión JA; Gómez A; Devesa MJ; Baliellas C; Castro Á; Ampuero J; Granados R; Pascasio JM; Rubín A; Salmeron J; Badia E; Planas JM; Lens S; Turnes J; Montero JL; Buti M; Esteban R; Fernández-Rodríguez CM
    J Viral Hepat; 2017 Apr; 24(4):304-311. PubMed ID: 27935168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
    Elsisi GH; Aburawash A; Waked E
    Value Health Reg Issues; 2017 Sep; 13():7-15. PubMed ID: 29073993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
    Smith DA; Bradshaw D; Mbisa JL; Manso CF; Bibby DF; Singer JB; Thomson EC; da Silva Filipe A; Aranday-Cortes E; Ansari MA; Brown A; Hudson E; Benselin J; Healy B; Troke P; McLauchlan J; Barnes E; Irving WL
    J Viral Hepat; 2021 Sep; 28(9):1256-1264. PubMed ID: 34003556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
    Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
    J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
    Belperio PS; Shahoumian TA; Loomis TP; Backus LI
    J Viral Hepat; 2019 Aug; 26(8):980-990. PubMed ID: 31012179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].
    Nan YM; Liu LD; Zhao W; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):919-922. PubMed ID: 31941253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options.
    Azzeri A; Dahlui M; Mohamed R; McDonald SA; Jaafar H; Shabaruddin FH
    Front Public Health; 2023; 11():1114560. PubMed ID: 36935675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
    Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
    JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
    Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
    J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
    Chen R; Xiong Y; Zeng Y; Wang X; Xiao Y; Zheng Y
    Front Public Health; 2023; 11():1179531. PubMed ID: 37841743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
    Soria A; Fava M; Bernasconi DP; Lapadula G; Colella E; Valsecchi MG; Migliorino GM; D'Ambrosio R; Landonio S; Schiavini M; Spinetti A; Carriero C; Degasperi E; Cologni G; Gatti F; Viganò P; Hasson H; Uberti-Foppa C; Pasulo L; Baiguera C; Rossotti R; Vinci M; Puoti M; Giorgini A; Menzaghi B; Lombardi A; Pan A; Aghemo A; Grossi PA; Boldizzoni R; Colombo S; Viganò M; Rumi MG; Del Poggio P; Valenti L; Giglio O; De Bona A; d'Arminio Monforte A; Colombo A; Spinelli O; Pigozzi MG; Molteni C; Bonfanti P; Terreni N; Perini P; Capretti A; Bella D; Liani C; Polo S; Aimo G; Pagnucco L; Bhoori S; Centenaro R; Graffeo M; Ciaccio A; Dionigi E; Lazzaroni S; Carderi I; Di Marco M; Rizzardini G; Noventa F; Lampertico P; Fagiuoli S
    Liver Int; 2020 Apr; 40(4):769-777. PubMed ID: 31970845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.
    Boyer S; Baudoin M; Nishimwe ML; Santos M; Lemoine M; Maradan G; Sylla B; Kouanfack C; Carrieri P; Mourad A; Rouveau N; Moh R; Seydi M; Attia A; Woode ME; Lacombe K
    BMC Health Serv Res; 2022 Mar; 22(1):303. PubMed ID: 35248039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.
    Rattanavipapong W; Anothaisintawee T; Teerawattananon Y
    PLoS One; 2018; 13(2):e0193112. PubMed ID: 29466415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
    Corman S; Elbasha EH; Michalopoulos SN; Nwankwo C
    Value Health; 2017 Sep; 20(8):1110-1120. PubMed ID: 28964443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
    Ruggeri M; Rolli FR; Kondili LA; Drago C; De Solda F; Nappi C; Cicchetti A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):363-374. PubMed ID: 30351994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.